PofoliaShared via Pofolia

International Journal of Retina and Vitreous· 2026Q1

Plasma rich in growth factors membrane for macular holes in eyes with pathological myopia without peeling of internal limiting membrane

Carlos Miguel Córdoba-Ortega, Juan David Arias, Jenyffer M. Barahona-Campos, Maira A. Gomez-Velasco et al.

Short summary

A 6-month follow-up study of 7 patients with pathological myopia and macular holes (MH) found that using a plasma-rich in growth factors membrane (PRGFm) achieved complete anatomic closure in all cases without internal limiting membrane (ILM) peeling, improving visual acuity from counting fingers to a median of 20/100.

AI-generated from the title and abstract; the full text is not read.

Key points

  • Complete macular hole closure achieved in 100% of 7 patients with pathological myopia using PRGFm.
  • The technique did not require internal limiting membrane (ILM) peeling.
  • Median visual acuity improved from counting fingers (2.0 logMAR) to 20/100 (0.7 logMAR) after 6 months.
  • No complications related to the PRGFm application were reported.

AI-generated from the title and abstract; the full text is not read.

Abstract

Abstract Background Myopic macular holes (MH) present a significant surgical challenge due to their low closure rates and poor visual prognosis. Conventional approaches frequently require internal limiting membrane (ILM) peeling, which adds surgical complexity and potential risks. Plasma rich in growth factors membrane (PRGFm) has emerged as a biological scaffold that promotes retinal repair and may facilitate MH closure without ILM manipulation. This study aims to evaluate the usefulness of PRGFm in improving closure of myopic macular holes without peeling of the ILM. Methods Observational study of a consecutive case series. Pathological myopia patients with MH. Best-corrected visual acuity (BCVA), optical coherence tomography (OCT) data, anatomic closure rates were documented. Results 7 patients who met the inclusion criteria were enrolled. Median follow-up was 6 months. The MH before surgery had a median size of 810 micrometers, most patients had a BCVA of counting fingers (CF) (2.0 logMAR). Complete macular hole closure was achieved in all cases, and median BCVA was 20/100 (0.7 logMAR). No complications related to PRGFm were found. Conclusion PRGFm is a valuable option for the treatment of MH in pathologic myopic eyes. Its application promotes tissue regeneration and facilitates anatomical closure. The technique is reproducible and does not require manipulation of the internal limiting membrane.

The authors' abstract, as published at the source. International Journal of Retina and Vitreous, 2026 · DOI ↗

TakeawaysPremium
Ask the paperFree account

Continue with a free account

Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.

Continue free on the web

Sign in with Google or Apple; no card needed. You come back to this paper.

On your phone:

Field: Radiology, Nuclear Medicine and Imaging

Radiology, Nuclear Medicine and ImagingMedicine